The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Managing cardiotoxicity associated with the use of ibrutinib
Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, talks on ibrutinib-associated cardiotoxicity, highlighting management strategies and the potential of switching to a second-generation BTK inhibitor. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis: Consultancy; Miltenyi Biotec: Consultancy, Research Funding; Lilly Oncology: Consultancy, Honoraria; Epizyme: Consultancy; Bristol Myers Squibb: Consultancy; Incyte Corporation: Consultancy, Honoraria, Speakers Bureau; TG therapeutics: Consultancy; Kite Pharma: Consultancy.
